c-MET Protein, Cynomolgus, Recombinant (His Tag)

1/1
Price:
Size:
Number:

c-MET Protein, Cynomolgus, Recombinant (His Tag): Product Information

Purity
(4.6+58.2+34.7) % as determined by SDS-PAGE
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method
Activity
Immobilized Cynomolgus MET-His at 10 μg/ml (100 μl/well) can bind biotinylated Cynomolgus HGF (cat:90286-CNAH), The EC50 of biotinylated Cynomolgus HGF (cat:90286-CNAH) is 0.11-0.27 μg/ml.
Protein Construction
A DNA sequence encoding the cynomolgus/rhesus MET (NP_001162100.1) (Met1-Thr932) was expressed with a polyhistidine tag at the C-terminus. Cynomolgus and Rhesus MET sequences are identical.
Accession#
Expressed Host
HEK293 Cells
Species
Cynomolgus
Predicted N Terminal
Glu 25
Molecule Mass
The recombinant cynomolgus/rhesus MET comprises 919 amino acids and has a calculated molecular mass of 103.1 KDa. The apparent molecular mass of it is approximately 128.2, 77.6 and 45.7 KDa in SDS-PAGE under reducing conditions.
Formulation
Lyophilized from sterile PBS, pH 7.4.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

c-MET Protein, Cynomolgus, Recombinant (His Tag): Images

c-MET Background Information

Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that has been shown to be overexpressed and/or mutated in a variety of malignancies. HGFR protein is produced as a single-chain precursor, and HGF is the only known ligand. Normal HGF/HGFR signaling is essential for embryonic development, tissue repair or wound healing, whereas aberrantly active HGFR has been strongly implicated in tumorigenesis, particularly in the development of invasive and metastatic phenotypes. HGFR protein is a multifaceted regulator of growth, motility, and invasion, and is normally expressed by cells of epithelial origin. Preclinical studies suggest that targeting aberrant HGFR signaling could be an attractive therapy in cancer.
Full Name
MET proto-oncogene, receptor tyrosine kinase
References
  • McGill GG, et al. (2006) c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem. 281(15): 10365-73.
  • Garcia S, et al. (2007) c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. British journal of cancer. 96(2): 329-35.
  • Socoteanu MP, et al. (2008) c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol. 14(19): 2990-4.
  • Kong DS, et al. (2009) Prognostic significance of c-Met expression in glioblastomas. Cancer. 115(1): 140-8.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait